Background: Minimal hepatic encephalopathy (MHE) is implicated in the impairment of memory function. Fibroblast growth factor-2 (FGF2) is involved in modulating synaptic and neuronal formation.
Introduction
Fibroblast growth factor-2 (FGF2) is most abundantly expressed in the central nervous system (CNS) by adulthood (1). Studies on rodents have found that released FGF2 primarily binds to FGF receptor-1 (FGFR1) located on the cell surface, though can interact with all 4 FGF receptors (2) . FGF2 is implicated in regulating many functions of CNS, such as, enhances neuronal survival and neurogenesis, facilitates dendritic growth (3, 4) and regenerative plasticity (5, 6) , and promotes synaptic formation (7) . Minimal hepatic encephalopathy (MHE) mainly is characterized by disruption in memory function detectable by electrophysiological tests (8) . However, the role of FGF2 in MHE pathology is unknown. We recently proposed that FGF2 might also be involved in modulating synaptogenesis underlying cognitive function in MHE rats.
Neuregulin-1 (NRG1), is a member of an active epithelial growth factor (EGF) family, identified as a transmembrane protein. NRG1 and its ErbB receptor tyrosine kinases, are expressed in the CNS, where NRG1 binds to and activates ErbB. They exert an essential role in regulating the synaptic plasticity, regeneration of the nervous system (9) (10) (11) and homeostasis of brain activity (12) . An abundant evidence suggests that NRG1 has been implicated in preventing brain injury following stroke (13, 14) and protecting neurons in Parkinson's disease (15) and Alzheimer's disease (AD) (16) . . Therefore, FGF2 may regulate the NRG1/ErbB4 pathway involved in synaptic formation in MHE.
Prior to the present study, the expression of FGF2 and its effect on cognitive function-which is associated with NRG1 secretion in MHE rats-had not been investigated. We hypothesized that reducing FGF2 levels in MHE rats would prevent cognitive decline by impairing the activation of NRG1/ErbB4 signaling and dowregulation of Sirt1.
Materials and methods

MHE models and treatment
Sprague-Dawley rats (220-250g) were purchased from the experimental animal center of the Chinese academy of sciences in Shanghai. The normal values of waterfinding task (WFT) and Y-maze (YM) of all animals were achieved before experimenting. To induce liver cirrhosis, animals (n=30) were injected (i.p.) with thioacetamid (TAA) (200 mg/kg in normal saline, Sigma-aldrich) twice per week for 8 weeks. TAA-treated rats were included to the HE group, if they exhibited symptoms of delayed motor activity, lethargy, and subsequent coma (17) . TAA-treated rats with no HE symptoms (n=22) were conducted to the WFT and YM to confirm MHE condition with the requirements for values of WFT higher than mean ±1.96·SD or values of YM lower than mean ±1.96·SD.
Normal and MHE rats were implanted with cannulae in the right lateral ventricles using stereotaxis instrument. MHE rats were intracerebroventricularly microinjected with FGF2 (0.6 μg/10 μl, 1.2 μg/10 μl) or NRG1 (5 μmol/5 μl, 10 μmol/5 μl) through a guide cannula for 3 times one week, or with 0.5 μg of FGF2, NRG1 plasmid or control plasmid pCMV-Tag2A for 24 h (Santa Cruz, CA, USA) (18) .
After injection, YM and WFT tests were conducted.
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Behavioral tests
For YM, rats were individually put at the end of an arm in a three arm apparatus to explore the maze freely for 8 min. Spontaneous alternation percentage (SA%), defined as a ratio of the arm choices to total choices, were measured (19) .
For WFT, Rats were individually put at the near-right corner of the WFT apparatus and allowed to find and drink the water in the alcove within 3min. Entry latency (EL, the elapsed times for entry into the alcove), contacting latency (CL, the elapsed times for the first touching/sniffing/licking of the water tube) and drinking latency (DL, the elapsed times for the initiation of drinking from the water tube) were measured (20, 21) .
Cell culture and treatments
Primary hippocampal rats neurons (PHNs) and Primary cortical rats neurons (PCNs) were obtained from respective hippocampus or cerebral cortex of 1-day-old Sprague-Dawley rat pups which were digested with trypsin and DNase, then plated in poly-L-lysine-precoated six-well plates with a density of 2×106 cells/well in Neurobasal® Medium (1X) supplemented with 0.5 mM GlutaMAX™-I, B-27® (22) .
Then PHNs or PCNs were treated with FGF2 or NRG1 (1, 5, 20 ng/ml) for 24 h in the presence or absence of 10 μg/ml polyclonal anti-NRG1 antibody (Origene, Rockville, MD), 50 μmol/L ErbB4 inhibitor AG1478 (Origene, Rockville, MD), or 10 μmol/L Sirt1 inhibitor sirtinol (Origene, Rockville, MD) for 24h, or treated with FGF2 (20 ng/ml) for 24 h after transfection with Silencer Negative Control #1 siRNA (scrambled siRNA), NRG1 or ErbB4 siRNA (0.25 μg, Santa Cruz, CA, USA).
RT-PCR and real-time quantitative PCR (qPCR)
cDNAs templates were synthesized from extracted total RNA using omniscript reverse transcriptase (Quiagen) and used to perform PCR amplification under the indicated conditions using Taq DNA polymerase (Sigma-Aldrich).
Real-time PCR results were normalized to GAPDH mRNA. The primers (Invitrogen) were as follows: NRG1, 5'AATGGACAGCAACACAAG3′ (Forward) and 5'TTAGCGATTACACTAGACAG3′ (Reverse); FGF2, 5'GAAGAGCGACCCTCACATCAAG3′ (Forward) and 5 5'CTGCCCAGTTCGTTTCAGTG3′ (Reverse); GAPDH, 5′TGTCATCAACGGGAAGCCCA3′ (Forward) and 5'TTGTCATGGATGACCTTGGC3′ (Reverse).
Measurement of FGF2 or NRG1 release
High sensitivity sandwich enzyme-linked immunosorbent assay (ELISA) kits were used to assay Extracellular FGF2 or NRG1 levels in the culture medium of primary neurons in 96-well plates. FGF2 or NRG1 levels were determined spectrophotometrically using a Thermo-Fisher Multiskan MCC plate reader according to the manufacturers' recommendations.
Immunoblotting (IB) analysis
The amount of protein was prepared from homogenized tissues or tells and determined using the Bradford quantification assay (Bio-Rad For coimmunoprecipitations, lysates of tissues or tells were incubated with antibodies overnight (4°C) and subsequently with protein G-agarose beads (Millipore) for 5h (4 °C). Beads were washed with lysis buffer, the eluent was separated by SDS-PAGE and electroblotted to PVDF membrane to probe proteins using primary and secondary antibodies.
Functional labeling of presynaptic boutons with FM4-64
5 mg/mL FM4-64 (Invitrogen) and 50 mM KCl in Hanks' balanced salt solution were used to incubate primary neurons for 1 min at 4°C. After reaction, free FM4-64
was removed by washing with Hanks' balanced salt solution.
Double-labeled fluorescent staining
Brain sections or glass coverslips were fixed with 4 % paraformaldehyde for 30 6 min, rupture of cell membrane was performed using 0.1% Triton X-100 for 10 min at room temperature, PBS containing 5% normal goat serum for 1 h at room temperature was used for blocking, and sections or coverslips were incubated overnight at 4 °C with the following primary antibodies: pErbB4, NRG, FGF2, Sirt1, syntaxin, Homer, and MAP2 (Abcam). Alexa Fluor 488 (green)/Alexa Fluor 594 (red) conjugated secondary antibody (Abcam, Cambridge, MA) were then used to detect primary antibodies for 1h. 
Statistical analysis
All of the data were indicated as mean ± SD. Data comparisons were determined using one-way analysis of variance (ANOVA). Dunnett's post hoc multiple comparison test was performed when significant differences were achieved by the ANOVA model. Then P values were adjusted by Bonferroni correction. The level of significance was determined for P < 0.05 or P < 0.01. All analyses were performed with SPSS 18.0 (PASW Statistics 18.0).
Results
FGF2 was reduced in the brain of the MHE rat model
FGF2 has been reported to be implicated in synaptogenesis and neuroprotection (23) . Based on this finding, we examined the expression of FGF2 in MHE rats.
Through IB analysis, the decrease in the expression of FGF2 levels were observed in the hippocampus and cortex of MHE rats ( Fig. 1a and b ). By IF staining, we also confirmed the reduced expression of FGF2 in cortex of MHE rats ( Fig. 1c ). RT-PCR ( Fig. 1d ) and qPCR ( Fig. 1e ) also showed the reduction of FGF2 transcription levels in the hippocampus and cortex of MHE rats, and ELISA assay showed the decrease in FGF2 levels in the hippocampus and cortex of MHE rats ( Fig. 1f ).
FGF2 elevated NRG1 release from neurons
NRG1 was previously found to be involved in synaptic plasticity (24, 25) . We hypothesized that FGF2 was implicated in the activation of NRG1 to regulate synaptic plasticity, and we set out to test the effect of FGF2 on NRG1 expression. First, we tested whether the FGF2 signaling extended to activate NRG1-ErbB4 signaling by neurons. The results of IB analysis, shown in Fig. 2a and b, indicated that maximal increases in NRG1 expression were achieved by 20 ng/ml FGF2, whereas a low dose of FGF2 did not alter the protein expression in PHNs, likewise, PCNs treated with FGF2 showed significant increase in NRG1 levels by 20 ng/ml ( Fig. 2a and b ). FGF2 treatment in PHNs significantly increased NRG1 levels by 24 hours; the same result was found in PCNs ( Fig. 2c and d) . IF staining confirmed the increased expression of NRG1 in PHNs in response to FGF2 ( Fig. 2e ). Using ELISA, the results showed that Unlike NRG1, we found that NRG2 or NRG3 levels were not changed by any concentration of FGF2 in PHNs ( Fig. 2j and k).
Next, we determined the impact of FGF2 on the ErbB4 expression. Interestingly, while 20 ng/ml FGF2 significantly stimulated phosphorylation of ErbB4 in PHNs and PCNs, other concentrations did not change phosphorylation of ErbB4, according to the IB analysis ( Fig. 3a and b ). The phosphorylation of ErbB4 was increased by 72 h in PHNs or PCNs when neurons were treated with 20 ng/ml FGF2 ( Fig. 3c and d ). As shown in Fig. 3e , the IF analysis confirmed that ErbB4 was strongly expressed in PHNs with a 20 ng/ml dose of FGF2 treatment. We examined the NRG1-ErbB4 interaction in neurons using coimmunoprecipitation. As shown in Fig. 3f , NRG1 was immunoprecipitated, and FGF2 treatment obviously increased the content of NRG1
and ErbB4 coimmunoprecipitated with NRG1 in PHNs in a dose-dependent fashion.
ErbB4 was also immunoprecipitated, and IB analysis showed that FGF2 induced the increase in ErbB4 and NRG1 coimmunoprecipitation with ErbB4 in neurons dosedependently. Unlike ErbB4, ErbB2 expression was not regulated by different concentrations of FGF2 in PHNs ( Fig. 3g and h ).
FGF2-induced synaptic formation was mediated by NRG1 signals in PHNs
Thinking that both FGF2 and NRG1 were involved in synaptic plasticity, and that FGF2 triggered release of NRG1, we investigated whether FGF2 induced synaptic activity via NRG1. As shown in Fig. 2g and h, increased syntaxin and Homer were observed in PHNs exposed to FGF2, while the addition of an anti-NRG1 antibody or AG1478 abolished these two proteins expressions ( Fig. 4a and b ).
Immunostaining confirmed that the increase in Homer level was abated by addition of an anti-NRG1 antibody or AG1478 in PHNs (Fig. 4c ). Using FM4-64 dye to probe activity-dependent synaptic vesicle recycling revealed that synaptic activity in PHNs with FGF2 treatment was markedly increased, but decreased with addition of the anti-NRG1 antibody or AG1478 ( Fig. 4d and e ).
Simultaneously, PHNs were transfected with NRG1 siRNA or ErbB4 siRNA plasmids. the results of transfection efficiency showed NRG1 protein level was significantly decreased in NRG1 siRNA-transfected PHNs by IB analysis ( Fig. 4f and g), and ErbB4 protein levels were also decreased in ErbB4 siRNA-transfected PHNs ( Fig. 4h and i ). Furthermore, we found that the FGF2-induced elevation of syntaxin and Homer was reversed by NRG1 siRNA or ErbB4 siRNA transfection in PHNs ( Fig.   4j and k). The elevated Homer from high-dose FGF2 treatment was reversed by NRG1 siRNA or ErbB4 siRNA transfection in PHNs. We further addressed the role of FGF2 in the modulation of dendritic spine density using anti-vGluT1 and anti-MAP2
antibodies. Double IF staining revealed that vGluT1-positive signals were significantly elevated in PHNs exposed to NRG1 ( Fig. 4l and m) . These results confirmed that FGF2 induced NRG1 release and the activation of NRG1/ErbB4, leading to synaptic formation.
Sirt1 was involved in FGF2-mediated synaptic formation
Sirt1 has been reported to be involved in cognitive function, and synaptogenesis (26) . We tested whether FGF2 and NRG1 elicited synaptic formation via Sirt1. FGF2 significantly increased thecontent of Sirt1 dose-dependently in PHNs ( Fig. 5a and b) .
PCNs showed the same results in the protein in response to FGF2 ( Fig. 5a and b ).
Sirt1 levels were elevated by 48 hours in PHNs after FGF2 treatment ( Fig. 5c and d) .
Immunostaining confirmed the elevation of Sirt1 expression in PHNs with a high dose of FGF2 ( Fig. 5e ). Neurons exposed to NRG1 showed dose-dependent increases in the expression of Sirt1 in PHNs and PCNs ( Fig. 5f and g). Sirt1 was increased by 20 ng/ml NRG1 treatment time-dependently ( Fig. 5h and i). As shown in Fig. 5j and k, the addition of sirtinol in PHNs abolished the FGF2-stimulated upregulation of syntaxin and Homer. The expressions of syntaxin and Homer were increased by NRG1, which was reversed by sirtinol ( Fig. 5l and m) . These results confirmed that FGF2 and NRG1 induced Sirt1 expression, leading to synaptogenesis.
NRG1 triggered FGF2 release from neurons
We then tested whether NRG1 in turn affected FGF2 release. IB analysis of cell lysates showed that NRG1 significantly gradually increased FGF2 in PHNs with a dose-dependent fashion, and FGF2 content in PCNs was elevated with a dosedependence in response to NRG1 ( Fig. 6a and b ). PHNs in response to NRG1 exhibited increases in FGF2 expression time-dependently ( Fig. 6c and d) . By immunostaining, NRG1 increased cell-bound FGF2 (Fig. 6e ) expression in PHNs.
The results of qPCR showed that FGF2 mRNA expression were increased by NRG1 dose-dependently in PHNs and PCNs (Fig. 6f ). NRG1 treatment revealed steady increases in FGF2 mRNA with time-dependent fashion in PHNs. Using ELISA assay, NRG1 (20 ng/ml) elevated the release of FGF2 dose-dependently ( Fig. 6h ) and timedependently in PHNs (Fig. 6i ).
FGF2 mitigated the inactivation of NRG1/ErbB4 signaling in brain
Next, we investigated whether FGF2 had the effect on the NRG1/ErbB4 signaling in vivo. As determined by IB analysis in Fig. 7a and b, NRG1/ErbB4 levels were significantly reduced in the hippocampi of MHE rats, whereas, administration of high FGF2 obviously restored the expression of the 2 proteins. However, low FGF2 did not alter NRG1/ErbB4 levels in MHE rats. We also observed the decrease in NRG1/ErbB4 expression in the cortices of MHE rats, which was blocked by FGF2 administration dose-dependently ( Fig. 7c and d) . Immunostaining of the cortices of MHE rats showed pronounced decrease in NRG1 levels, which were diminished by administration of high FGF2 (Fig. 7e) . At the same time, IB analysis showed that FGF2 protein levels were significantly increased in the hippocampi and cortices of normal rats with FGF2 gene transfection compared to normal rats and in the hippocampi and cortices of MHE rats with FGF2 gene transfection compared to MHE rats ( Fig. 7f and g) , indicating high transfection efficiency. Then, we found that NRG1/ErbB4 protein levels were significantly increased in the hippocampi of MHE rats, and FGF2 transfection blocked the decrease ( Fig. 7h and i) . The cortices of MHE rats showed decrease in NRG1/ErbB4 protein levels, which was inhibited by FGF2 transfection (Fig. 7j and k) . Using IF staining, we confirmed that the strong expression of ErbB4 was induced after Wnt5a transfection (Fig. 7l ). IB analysis from hippocampal lysates showed that the decrease in pFGFR1 levels in MHE rats was reversed by FGF2 administration (Fig. 7m and n) . The pFGFR1 levels were reduced in the cortices of MHE rats ( Fig. 7o and p) , while FGF2 transfection blocked this protein. These data suggest that the administration of FGF2 activated the NRG1/ErbB4 signaling by the brain of MHE rats.
FGF2 attenuated the disruption of synaptic formation in vivo
We assessed the effect of FGF2 on synaptic formation. As indicated by the IB analysis of the hippocampi of MHE rats showed the reduction of syntaxin and Homer expression, and FGF2 administration resulted in an increase in the 2 proteins; NRG1 administration also diminished the proteins in. Syntaxin/Homer expression ( Fig. 8c and d) was significantly decreased in the cortices of MHE rats, whereas, administration of FGF2 and NRG1 reversed the expression of the 2 proteins. As shown by IF staining, MHE rats displayed lower expression of Homer, and administration of NRG1 increased the expression of this protein, while administration of FGF2 diminished the decrease in the protein (Fig. 8e) .
Similarly, IB analysis showed that NRG1 protein levels were obviously increased in the hippocampi and cortices of normal rats with NRG1 gene transfection compared to normal rats and in the hippocampi and cortices of MHE rats with NRG1
gene transfection compared to MHE rats ( Fig. 8f and g) . Then, we found that syntaxin/Homer expressions were decreased in the hippocampi of MHE rats, which was blocked after FGF2 transfection; NRG1 transfection also abated the decrease in the 2 proteins ( Fig. 8h and i) . IF analysis showed that the decrease in syntaxin expression in cortices of MHE rats was diminished by FGF2 transfection or NRG1 transfection ( Fig. 8j ), FGF2 transfection facilitated higher expression of Homer than that of cortice of MHE rats; NRG1 transfection had the same effect (Fig. 8k) . These results suggest that FGF2 improved the production of synaptic proteins in the brain of MHE rats.
FGF2 prevented memory impairment in MHE rats
We examined whether FGF2 or NRG1 impacted on cognitive function in vivo.
For YM test, the SA% of MHE rats was significantly decreased, and the decrease was reversed by NRG1 or FGF2 administration (Fig. 9a ). NRG1 or FGF2 transfection to MHE rats significantly increased SA% (Fig. 9b ). For WFT test, EL, CL, and DL were obviously increased in MHE rats, which were recovered to the normal level by administration of NRG1 or FGF2 (Fig. 9c ). NRG1 or FGF2 transfection to MHE rats markedly restored EL, CL, and DL (Fig. 9d) . These results suggest that the administration of FGF2 or NRG1 reversed the cognitive deficit observed in MHE rats.
Discussion
Our present study identified NRG1/ErbB4 as a primary downstream effector of FGF2, essential for the signaling of synaptic formation. FGF2 signals mediated the activation of NRG1/ErbB4 via FGFR1, and the process was linked to the expression of Sirt1 proteins, which are sensitive to synaptic formation in neurons. We found that downregulation of FGF2 in neurons induced the inactivation of NRG1/ErbB4 signaling and downstream Sirt1, which disrupted synaptic formation, leading to the pathogenesis of MHE.
Despite the beneficial effects of FGF2 on neuron protection, synaptic plasticity, and memory function, little is known about its relationship with the pathogenesis of MHE. Our results showed that FGF2 administration immediately facilitates synaptic transmission and memory function in MHE rats. Together, our evidence supported that FGF2 played a key role in modulating synaptogenesis through the molecular cascade. our study revealed an FGF2-dependent synaptic response in neurons.FGF2
can bind to all 4 FGF receptors, located on the cell surface, but interacts with the main receptor FGFR1 (2) . Compelling evidence showed that synaptic formation is critically facilitated by FGF2. Studies have shown that reduced FGFR1 in MHE rats was consistent with FGF2 levels. We found that decrease in FGF2 levels, but no alteration of expressions of the other FGF subfamily protein in MHE brains. The most notable finding was that the synapses were fully strengthened by administration of FGF2. The disruption of synaptic formation and the impairment of memory function were improved by FGF2 administration in MHE rats.
NRG1 is characterized by ligands of the ErbB receptor family. (27, 28) . NRG1 possesses \an epidermal growth factor domain that is required for binding and activating ErbB3 or ErbB4 (29) ., The adult brain widely expressed NRG1 and ErbB kinases (30) . Furthermore, the enrichment of postsynaptic ErbB4 in particular is at excitatory synapses (31, 32) . FGF2 protein in neurons leads to increased NRG1/ErbB4 activation. Activation of ErbB4 by binding to NRG1 affects a number of neural development, including neurotransmission, neuroplasticity (33, 34) , or pyramidal neuron synaptic plasticity (32, 35, 36) , and therefore impacts on behavior alteration. We wanted to identify the mechanism for the induction of MHE through the reduction of FGF2 levels. In this study, we found that FGF2 is involved in regulating the NRG1 production and secretion involved in synaptic formation, and that the concentration of NRG1 is altered in the brains of MHE rats. These findings suggest that FGF2 induced the reduction of neuronal NRG1 release involved in the pathogenesis of MHE.
We found that NRG1 is significantly downregulated, and that NRG1administration induced the restoration of the synaptic dysfunction seen in MHE brains. The addition of NRG induced a further increase in presynaptic marker (syntaxin) and post-synaptic marker (Homer) levels. FGF2 administration triggered the activation of NRG1/ErbB4 signaling in MHE rats. The reduction of FGF2 induced synaptic dysfunction and led to cognitive impairment via the inhibition of NRG1. We found that FGF2 may act through NRG1 activation, and regulation of NRG1 is important for synaptic spine formation. Furthermore, we found that NRG1 is a critical factor for inducing FGF2 secretion. Taken together, these findings indicate that exogenous decreased FGF2 may be associated with the reduction of NRG1 expression under MHE conditions, and both of FGF2 and NRG1 led to memory improvement.
Mammalian Sirt1, characterized as a NAD+-dependent histone deacetylase (37) , is expressed in the hypothalamus (38) . Moreover, mounting evidence implicates that Sirt1 is identified as a critical factor for normal synaptogenesis and cognitive function (26, 39) . Therefore, Sirt1 is indispensable for cellular mechanisms underlying synaptic formation in rats. Our results demonstrate that FGF2 appears to facilitate the expressions of synaptic proteins via Sirt1, it is likely that FGF2 modulates learning and memory function through NRG1/ErbB4/Sirt1 signaling.
Conclusions
our study demonstrated that FGF2 regulates dendritic spine generation and synaptic formation via NRG1 release and Sirt1 expression. Our findings also showed that FGF2 expression is decreased in MHE brain, and that FGF2 treatment mitigates the disruption of synaptic formation and memory impairment via neuronal NRG1/ErbB4 signaling. These findings highlight FGF2 as a promising potential treatment for MHE.
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